Found 10 bookmarks
Custom sorting
Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes New-User, Active-Comparator Analysis
Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes New-User, Active-Comparator Analysis

Study in the US during the Omicron wave followed 248 metformin users over 6 months.

Starting metformin within a week of COVID reduced the risk of Long COVID or death by 53%.

Safe and inexpensive with results aligning with earlier data.

·natap.org·
Metformin reduces the risk of Long COVID or Death over 6 months in an Emulated Target Trial of Primarily Omicron-infected Adults without Diabetes or Prediabetes New-User, Active-Comparator Analysis
I'm the acupuncturist/herbalist who told everyone to take Berberine, Taurine, Lumbrokinase, and Minerals for Long Covid. The protocol is strictly palliative, meant to improve QoL. The work I've done since then on Lingering Pathogenic illness and TCM is meant to be curative, a WIP
I'm the acupuncturist/herbalist who told everyone to take Berberine, Taurine, Lumbrokinase, and Minerals for Long Covid. The protocol is strictly palliative, meant to improve QoL. The work I've done since then on Lingering Pathogenic illness and TCM is meant to be curative, a WIP
·x.com·
I'm the acupuncturist/herbalist who told everyone to take Berberine, Taurine, Lumbrokinase, and Minerals for Long Covid. The protocol is strictly palliative, meant to improve QoL. The work I've done since then on Lingering Pathogenic illness and TCM is meant to be curative, a WIP
Feels like a good time for a thread about all things exercise for people living with infection (and exposure)-associated complex chronic illnesses (IACCs) such as , and chronic /tick- and vector-borne illness. Let’s start with a trip down memory lane. 🧵 1/
Feels like a good time for a thread about all things exercise for people living with infection (and exposure)-associated complex chronic illnesses (IACCs) such as , and chronic /tick- and vector-borne illness. Let’s start with a trip down memory lane. 🧵 1/
“Feels like a good time for a thread about all things exercise for people living with infection (and exposure)-associated complex chronic illnesses (IACCs) such as #MECFS, #LongCOVID and chronic #Lyme /tick- and vector-borne illness. Let’s start with a trip down memory lane. 🧵 1/“
·x.com·
Feels like a good time for a thread about all things exercise for people living with infection (and exposure)-associated complex chronic illnesses (IACCs) such as , and chronic /tick- and vector-borne illness. Let’s start with a trip down memory lane. 🧵 1/
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial

“Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo.

When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo.

There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo.

…Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.”

·thelancet.com·
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

(So of course we will probably never get access to this.)

“The goal of this study is to confirm that niclosamide can solve the complex symptoms of Long COVID through multiple mechanisms such as virus suppression, inflammation suppression, and neuroprotection. We hope that the clinical trial will be successful and provide a practical treatment option for Long COVID patients, which will be historic."

The goal of this study is to confirm that niclosamide can solve the complex symptoms of Long COVID through multiple mechanisms such as virus suppression, inflammation suppression, and neuroprotection. We hope that the clinical trial will be successful and provide a practical treatment option for Long COVID patients, which will be historic."
·morningstar.com·
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD